BioCryst to present new Orladeyo (berotralstat) real-world data at 2024 American Academy of Allergy, Asthma & Immunology annual meeting
BioCryst Pharmaceuticals Inc today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
The meeting will take place at the Walter E. Washington Convention Center in Washington, DC, from 23-26 February 2024. The five abstracts that BioCryst will present are:
- Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday 23rd February, 3:15-4:15 p.m. ET; Convention Center, Level 2, Hall D
- Consistently Low Hereditary Angioedema Attack Rates with Berotralstat Regardless of Prior Prophylaxis: Real-World Outcomes; Poster #008; Friday, 23rd February, 3:15-4:15 p.m. ET; Convention Center, Level 2, Hall D
- Assessment of the Tolerability and Effectiveness of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Berolife Study Interim Analysis; Poster #028; Friday 23rd February, 3:15-4:15 p.m. ET; Convention Center, Level 2, Hall D
- Evaluation of Adherence to Berotralstat in Patients with Hereditary Angioedema: A Prospective Survey in Community Pharmacies; Poster #023; Friday 23rd February, 3:15-4:15 p.m. ET; Convention Center, Level 2, Hall D
- Real-World Effectiveness of Berotralstat in HAE With and Without C1-Inhibitor Deficiency; Poster #281; Saturday 24th February, 9:45-10:45 a.m. ET; Convention Center, Level 2, Hall D
(Source: BioCryst)
